Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Tibulizumab in Hidradenitis Suppurativa. The expected timing is based on the latest available company guidance and may change.
TibuSHIELD Study. 5/20/25- Launched Ph2 trial. Topline results for primary efficacy endpoint at Wk 16, key secondary & exploratory outcomes in Q3 2026. 01/12/26:- Enrollment expanded to 225 in Ph2 TibuSHIELD HS study; topline data now expected Q4 2026. 05/07/26:- TibuSHIELD Ph2 HS trial enrolling ~225 patients on track; topline Q4 2026 reiterated. 06/29/26:- TibuSHIELD Ph2 enrollment completed (247). Topline data still expected Q4 2026. 08/11/26:- TibuSHIELD Ph2 enrollment completed at 247; topline Q4 2026 reiterated.
Verification
Confirm timing and program details against the company announcement or filing.